Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
MGUS
SMM
immune microenvironment
multiple myeloma
plasma cells
single-cell RNA sequencing
tumor microenvironment
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
ppublish
Résumé
Precursor states of Multiple Myeloma (MM) and its native tumor microenvironment need in-depth molecular characterization to better stratify and treat patients at risk. Using single-cell RNA sequencing of bone marrow cells from precursor stages, MGUS and smoldering myeloma (SMM), to full-blown MM alongside healthy donors, we demonstrate early immune changes during patient progression. We find NK cell abundance is frequently increased in early stages, and associated with altered chemokine receptor expression. As early as SMM, we show loss of GrK
Identifiants
pubmed: 33409501
doi: 10.1038/s43018-020-0053-3
pmc: PMC7785110
mid: NIHMS1651990
pii: 10.1038/s43018-020-0053-3
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
493-506Subventions
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181683
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205954
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008313
Pays : United States
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
COMPETING INTERESTS STATEMENT G.G. receives research funds from IBM and Pharmacyclics. I.M.G. has a consulting/advisory role with GSK, AbbVie, Bristol-Myers Squibb (BMS). I.M.G has a consulting role with Sanofi, Janssen, Takeda, Celgene, Karyopharm, GNS, Cellectar, Medscape, Genetech, Adaptive, Aptitude, Curio Science, Magenta, Oncopeptides. I.M.G. received research funding/ honoraria from Celgene, Takeda, BMS, Janssen Pharmaceuticals, and Amgen.
Références
Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962–2972 (2008).
pubmed: 18332230
pmcid: 2265446
Landgren, O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am. Soc. Hematol. Educ. Program 2013, 478–487 (2013).
pubmed: 24319222
Rajkumar, S. V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 57–65 (2011).
pubmed: 21181954
Kyle, R. A. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24, 1121–1127 (2010).
pubmed: 20410922
pmcid: 7020664
Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106, 812–817 (2005).
pubmed: 15855274
pmcid: 1895159
Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738–1744 (2013).
pubmed: 23515097
pmcid: 3773463
Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724–1732 (2006).
pubmed: 16705089
pmcid: 1895503
Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100–113 (2017).
pubmed: 27531699
Bladé, J., Dimopoulos, M., Rosiñol, L., Rajkumar, S. V. & Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 28, 690–697 (2010).
pubmed: 20026810
Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).
pubmed: 17582068
Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412–5417 (2009).
pubmed: 19179464
pmcid: 2689042
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
pubmed: 10647931
Tyekucheva, S. et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat. Commun. 8, 420 (2017).
pubmed: 28871082
pmcid: 5583238
Glavey, S. V. et al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia 31, 2426–2434 (2017).
pubmed: 28344315
El-Haibi, C. P. et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl Acad. Sci. USA 109, 17460–17465 (2012).
pubmed: 23033492
Pearce, O. M. T. et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 8, 304–319 (2018).
pubmed: 29196464
Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).
pubmed: 18438415
Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320–329 (2015).
pubmed: 25706628
Petitprez, F. et al. PD-L1 expression and CD8
pubmed: 28753812
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
pubmed: 12529460
Podar, K., Hideshima, T., Chauhan, D. & Anderson, K. C. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin. Ther. Targets 9, 359–381 (2005).
pubmed: 15934921
Klein, B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin. Hematol. 32, 4–19 (1995).
pubmed: 7878477
Sawanobori, M. et al. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol. 98, 150–154 (1997).
pubmed: 9352746
Pessoa de Magalhães, R. J. et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98, 79–86 (2013).
pubmed: 22773604
pmcid: 3533663
Bailur, J. K. et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 4, e127807 (2019).
pmcid: 6629164
Leone, P. et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8
pubmed: 26185130
pmcid: 4592278
Kawano, Y. et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J. Clin. Invest. 128, 2487–2499 (2018).
pubmed: 29558366
pmcid: 5983341
Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290–4300 (2017).
pubmed: 28249894
pmcid: 5540790
Ramachandran, I. R. et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol. 190, 3815–3823 (2013).
pubmed: 23460744
pmcid: 3608837
Nakamura, K. et al. Dysregulated IL-18 Is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell 33, 634–648.e5 (2018).
pubmed: 29551594
Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625–3628 (2009).
pubmed: 19710503
pmcid: 2766678
De Beule, N. et al. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. J. Pathol. 241, 534–546 (2017).
pubmed: 27976373
Osterborg, A., Nilsson, B., Björkholm, M., Holm, G. & Mellstedt, H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur. J. Haematol. 45, 153–157 (1990).
pubmed: 1699786
Scavelli, C. et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 27, 663–674 (2008).
pubmed: 17667938
Minnie, S. A. et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 132, 1675–1688 (2018).
pubmed: 30154111
Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785–789 (2008).
pubmed: 17942755
pmcid: 2200851
Perussia, B. Fc receptors on natural killer cells. Curr. Top. Microbiol. Immunol. 230, 63–88 (1998).
pubmed: 9586351
Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).
pubmed: 31477722
pmcid: 6718415
Bernardini, G., Sciumè, G. & Santoni, A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front. Immunol. 4, 12 (2013).
pubmed: 23386850
pmcid: 3558687
Baecher-Allan, C., Wolf, E. & Hafler, D. A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 176, 4622–4631 (2006).
pubmed: 16585553
Karalis, K. et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254, 421–423 (1991).
pubmed: 1925600
Bratke, K., Kuepper, M., Bade, B., Virchow, J. C. Jr. & Luttmann, W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8
pubmed: 16106370
Ahn, E. et al. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl Acad. Sci. USA 115, 4749–4754 (2018).
pubmed: 29654146
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8
pubmed: 26034050
pmcid: 4493417
Roccaro, A. M. et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 12, 622–635 (2015).
pubmed: 26190113
pmcid: 4961259
Brown, R. D. et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk. Lymphoma 50, 1860–1864 (2009).
pubmed: 19883313
Raitakari, M. et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br. J. Haematol. 110, 203–209 (2000).
pubmed: 10930999
Tienhaara, A. & Pelliniemi, T. T. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Lab. Haematol. 16, 213–223 (1994).
pubmed: 7828409
Wu, L. et al. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol. Immunother. 60, 61–73 (2011).
pubmed: 20848094
Jurisic, V., Srdic, T., Konjevic, G., Markovic, O. & Colovic, M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med. Oncol. 24, 312–317 (2007).
pubmed: 17873307
Ponzetta, A. et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 75, 4766–4777 (2015).
pubmed: 26438594
Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).
pubmed: 27809856
pmcid: 5093947
Castella, B., Foglietta, M., Riganti, C. & Massaia, M. Vγ9Vδ2 T Cells in the bone marrow of myeloma patients: a paradigm of microenvironment-induced immune suppression. Front. Immunol. 9, 1492 (2018).
pubmed: 30013559
pmcid: 6036291
Chan, A. C. et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin. Exp. Immunol. 175, 49–58 (2014).
pubmed: 24032527
Dhodapkar, M. V. & Richter, J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin. Immunol. 140, 160–166 (2011).
pubmed: 21233022
pmcid: 3224820
Castella, B., Melaccio, A., Foglietta, M., Riganti, C. & Massaia, M. Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma. Front. Oncol. 8, 508 (2018).
pubmed: 30460198
pmcid: 6232124
Ortiz, M. L., Lu, L., Ramachandran, I. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol. Res. 2, 50–58 (2014).
pubmed: 24778162
Fang, Z. et al. Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. Oncotarget 8, 54173–54186 (2017).
pubmed: 28903332
pmcid: 5589571
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
pubmed: 22437938
pmcid: 3587148
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
pubmed: 24202395
pmcid: 3954707
Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601
pmcid: 5241818
Taylor-Weiner, A. et al. Scaling computational genomics to millions of individuals with GPUs. Genome Biol. 20, 228 (2019).
pubmed: 31675989
pmcid: 6823959
Tan, V. Y. F. & Févotte, C. Automatic relevance determination in nonnegative matrix factorization with the β-divergence. IEEE Trans. Pattern Anal. Mach. Intell. 35, 1592–1605 (2013).
pubmed: 23681989